Month 2025-10 — Hartwig Medical Actin: Focused on improving data integrity in panel specifications and enabling flexible gene filtering to support future strategies. Key features delivered: - Flexible gene filtering architecture via GeneFilter interface, decoupling filtering logic from a static known-genes set and enabling different filtering strategies. Commit: 34c19e5ee452129559863d1e448d163538d334a7 (ACTIN-2636: Refactor to use GeneFilter #1332). Major bugs fixed: - Enforced validation to ensure only known genes are used when deriving panel specifications; now throws IllegalStateException on unknown genes to maintain data integrity. Commit: 373b98466a6128291cf405ce8cfa67fcb918a54c (ACTIN-2636: Do not allow erroneous genes when deriving panel specs #1328). Overall impact and accomplishments: - Strengthened data integrity for panel specification processing, reducing risk of invalid inputs propagating downstream. - Improved maintainability and extensibility of gene filtering, enabling safer experimentation with filtering strategies. - Paved the way for faster, safer iterations on panel specs and related analytics. Technologies/skills demonstrated: - Java: exception handling (IllegalStateException) and interface-based design (GeneFilter). - Refactoring for modularity and future-proofing of the panel spec processing pipeline.

August 2025: Delivered key architectural improvements in Actin, focusing on deprecation/removal of trial functionality and refactoring the cohort availability model to support per-location capacity planning. These changes simplify the product surface, reduce maintenance overhead, and lay the groundwork for location-aware analytics while preserving backward compatibility.

July 2025 monthly summary for hartwigmedical/actin: Delivered impactful feature and reliability improvements with a focus on business value and maintainability. Key feature delivery includes driver likelihood estimation enhanced by sample-specific Tumor Mutational Burden (TMB) and the introduction of DndsModel to support driver likelihood assessments, enabling more patient-specific inferences. A major bug fix ensured robust failure signaling across molecular tests by propagating FAIL when any test fails and supporting a custom precedence in the combine logic. Documentation improvements consolidated the clinical datamodel guidance by moving it into datamodel README for easier access and onboarding. All changes are traceable to specific commits for auditability. Impact and value: Improved accuracy of driver likelihood estimates, more reliable molecular test outcomes, faster onboarding for new contributors through centralized docs, and stronger maintainability of the data model. Technologies and skills demonstrated: Python refactoring and modeling (TMB-based estimation, DndsModel), test orchestration and failure signaling, documentation best practices and Git-based traceability.

June 2025 summary: Focused on improving evidence-based treatment matching, robust data ingestion, and architecture clean-up. Delivered major features including ActionabilityMatcher for unified trial and evidence matching, standardized evaluation messaging, a flexible LocalDateTime deserializer for measurement dates, and the externalization of the clinical module into a dedicated repository. These changes improve clinical decision support accuracy, reduce message ambiguity, increase ingestion reliability, and enable independent deployment of clinical functionality. Key outcomes include clearer evaluation results, reduced maintenance overhead, and a more scalable core Actin platform.

May 2025 monthly accomplishments for hartwigmedical/actin and bioconda/bioconda-recipes. Delivered key features, fixed a critical diagnostic messaging bug, and expanded deployment capabilities. Focused on business value: improved decision support, data reliability, and deployment reach.

In April 2025, Actin delivered key molecular data quality and environment improvements that enhance data reliability and runtime security. The work focused on refining molecular data ingestion and evaluation, expanding coverage, and upgrading the platform stack to Java 17. These efforts reduce downstream data errors, enable more accurate decision-making in research pipelines, and position Actin for continued compliance and performance improvements.

March 2025 monthly summary for hartwigmedical/actin: Delivered data-driven enhancements to genetic test reporting by deriving tested genes from identified mutations and explicit 'no mutation found' entries, increasing accuracy and completeness of sequencing results. Refined IHC result curation to prioritize patient-specific data, enabling combination of patient IDs with IHC strings and filtering erroneous entries for unrelated patients, reducing mis-curations. Introduced external configuration for panel gene lists via TSV, enabling regex-based mapping of test names to genes and improving maintainability. Performed a serve package upgrade to maintain build compatibility; no functional changes observed, ensuring a stable deployment foundation. Overall impact: improved test result fidelity and curation quality, reduced config maintenance, and a more robust build/deploy baseline. Technologies/skills demonstrated: data-driven configuration, regex-based mapping, patient-ID filtering logic, package management, and maintainability patterns.

February 2025 — Actin (hartwigmedical/actin): Delivered hospital-contextual trial reporting enhancements and dynamic UI improvements to increase data accuracy, reduce noise, and accelerate decision-making for hospital teams. Key changes include dynamic trial tables with isHospital context, EMC compatibility, and refined trial matching logic; driver table extended with trial locations; targeted UI behaviors such as conditional acronym display and hiding non-relevant tables to minimize clutter. Implemented through commits ACTIN-1738, ACTIN-1741, ACTIN-1754, and ACTIN-1762. Business value includes faster, more accurate reporting across hospitals, improved data visibility, and better compliance with EMC requirements. Demonstrated skills: front-end data-driven rendering, hospital-context modeling, UI/UX refinement, and cross-commit integration.

January 2025 monthly summary for hartwigmedical/actin: Implemented a refactor of Trial Data Ingestion to use ACTIN's internal data model, removing validation and status management from ingestion flow and centralizing conversion logic. This enhances integration with eligibility rule parsing and treatment databases and enables smoother future enhancements.

December 2024: Delivered two high-impact features in hartwigmedical/actin focused on data modeling, data quality, and treatment matching reliability. The work improves performance, data consistency, and maintainability while enabling more accurate patient-centric decisions.

November 2024 (hartwigmedical/actin): Delivered performance, data quality, and reporting enhancements across key domains including CI/CD efficiency, treatment history modeling, external trial reporting, molecular data presentation, and trial status normalization. These changes shorten deployment cycles, improve clinical data fidelity, and enhance reporting capabilities for trials and molecular data.

October 2024 — hartwigmedical/actin: Focused on building and integrating automated regression testing for system reports to improve reliability and release confidence. Delivered a comprehensive regression testing framework, Dockerized build agents with visual PDF comparison tools, and CI/CD integration to detect changes in report generation via textual and visual comparisons. No explicit bug fixes reported this month; emphasis on high-impact features and automation to reduce risk and manual validation.